APPROACH UNDER REVIEW: `rag`

SCENARIO ID: scenario_19
APP DESCRIPTION: Anchor is a recovery companion for substance-use disorder: substance log, relapse-risk score, anonymous peer-support chat, optional integration with addiction clinics. EU + CH. Strict privacy posture — many users fear employer or insurer learning of use.

DEVELOPER PERSONA: Founder, recovery-services veteran.

EXPECTED HERA DIMENSIONS (gold standard): P1.D4, P2.D1, P2.D2, P2.D3, P2.D5, P2.D6, P3.D2, P5.D2, P6.D2, P7.D4

TRANSCRIPT:
### USER
Anchor is a recovery companion for substance-use disorder: substance log, relapse-risk score, anonymous peer-support chat, optional integration with addiction clinics. EU + CH. Strict privacy posture — many users fear employer or insurer learning of use.

### ASSISTANT
Let’s begin by identifying the **HERA dimensions** and **regulatory risks** relevant to Anchor. First, consider the **purpose** and **data processing** involved in your app.

### Reflection Question 1:  
**What is the primary purpose of the app, and how does it interact with health data?**  
- Is the app primarily a **wellness tool** (e.g., tracking substance use without making diagnostic claims)?  
- Or does it **screen for mental health conditions** (e.g., relapse-risk score) or **provide clinical advice** (e.g., optional integration with addiction clinics)?  

This distinction is critical for determining whether the app falls under **ISO/IEC 82304-2** (health software quality) or **MDR (Medical Device Regulation)**. For example, if the app provides **clinical advice** or **diagnostic claims**, it may fall under **MDR Class IIa or higher** [card_iso_82304 · p.0].  

### Reflection Question 2:  
**How does the app handle user data, particularly health data, and what are the data processing activities?**  
- Does the app **collect, store, or transmit health data** (e.g., substance use logs, relapse-risk scores)?  
- Are users **explicitly informed** about how their data is used, and is there a **clear privacy notice**?  

This relates to **GDPR Article 6** (legal basis for processing) and **Article 9** (special categories of data, such as health data) [card_gdpr_base · p.0]. If the app processes **health data**, it must satisfy **Article 9 conditions**, such as explicit consent or a legal basis like **vital interests**.  

### Reflection Question 3:  
**Does the app meet accessibility requirements under the EAA (European Accessibility Act)?**  
- Is the app **WCAG 2.1 AA compliant**, especially for users with disabilities?  
- Are features like **peer-support chat** and **onboarding flows** accessible to screen-reader users and other assistive technologies?  

This is relevant to the **Digital accessibility (WCAG/EN 301 549)** and **Inclusive design** dimensions of HERA [card_eaa_accessibility · p.0].  

### Reflection Question 4:  
**How does the app handle data monetization or third-party sharing?**  
- Does the app **share user data** with third parties (e.g., analytics providers, advertising partners)?  
- If so, is there **explicit, granular, purpose-specific consent** for each monetization activity, and are users informed about the **recipients and purposes**?  

This touches on **data monetization** and **ePrivacy** requirements, including **Art. 9(2)(a)** of GDPR and **Art. 5(3)** of ePrivacy Regulation [card_data_monetization · p.0].  

### Next Steps:  
Let’s now drill into **one specific risk** you’ve identified: the **strict privacy posture** and **user concerns about employer or insurer learning of use**. This relates to **data minimization**, **security**, and **transparency**.  

Would you like to explore this risk further?

### USER
Class I; relapse-risk score informational.

### ASSISTANT
Great! Based on your clarification that **Anchor is Class I** and the **relapse-risk score is informational**, let's now focus on the **HERA dimensions** and **regulatory risks** relevant to this classification.

---

### **HERA Dimension: Device Qualification & Class**  
**[P1.D1]**  
Since Anchor is classified as **Class I**, it is not subject to **Notified Body involvement** or **full design-dossier review** under the **MDR**. However, this classification still requires **compliance with health software quality standards** (e.g., **ISO/IEC 82304-2**) and **data protection laws** (e.g., **GDPR**).

---

### **HERA Dimension: Clinical Evidence**  
**[P2.D2]**  
Even though the **relapse-risk score is informational**, it may still require **clinical validation** to ensure that the score is **not misleading** or **overly deterministic**. For example, if the score is based on **machine learning models**, you should consider:

- **Validation of the model’s accuracy** and **reliability** (e.g., through **clinical evaluation** or **clinical performance data**) [card_clinical_eval_mdsw · p.0].
- Whether the score could **influence user behavior** (e.g., leading to self-diagnosis or unnecessary anxiety).
- Whether the score is **transparent** and **explainable** to users, especially if it is used to **inform treatment decisions**.

---

### **HERA Dimension: Data Protection & Privacy**  
**[P3.D1]**  
Given the **strict privacy posture** and **user concerns about employer or insurer learning of use**, this is a **critical area** for compliance with **GDPR** and **ePrivacy Regulation**.

#### **Key Considerations:**
- **Data minimization**: Are you only collecting the **minimum necessary data** to provide the service (e.g., substance logs, relapse-risk scores)?  
- **Purpose limitation**: Are you using the data **only for the purposes stated** (e.g., recovery support, peer support)?  
- **Transparency**: Are users **explicitly informed** about how their data is used, including **data sharing** with third parties (e.g., addiction clinics)?  
- **Security**: Are you implementing **appropriate technical and organizational measures** (e.g., encryption, access controls) to protect user data?

#### **Regulatory Reference:**
- **GDPR Article 6** (legal basis for processing) and **Article 9** (special categories of data, such as health data) [card_gdpr_base · p.0].
- **ePrivacy Regulation Article 5(3)** (consent for data processing) [card_eprivacy · p.0].

---

### **HERA Dimension: Accessibility & Inclusive Design**  
**[P4.D1]**  
Given the **peer-support chat** and **onboarding flows**, accessibility is crucial to ensure that **all users**, including those with **disabilities**, can use the app effectively.

#### **Key Considerations:**
- Is the app **WCAG 2.1 AA compliant** for **screen-reader users** and **keyboard navigation**?
- Are **visual and auditory cues** properly supported for users with **visual or hearing impairments**?
- Is the **language and content** accessible to users with **cognitive disabilities**?

#### **Regulatory Reference:**
- **European Accessibility Act (EAA)** [card_eaa_accessibility · p.0].

---

### **HERA Dimension: Data Monetization & Third-Party Sharing**  
**[P5.D1]**  
If the app **monetizes user data** (e.g., through analytics or advertising), you must ensure:

- **Explicit, granular, purpose-specific consent** is obtained for each data processing activity [card_data_monetization · p.0].
- Users are **informed** about the **recipients and purposes** of their data.
- Data is **not shared** with third parties **without user consent**, especially if it involves **health data**.

---

### **HERA Dimension: User Control & Transparency**  
**[P6.D1]**  
Given the **privacy concerns**, it's essential to provide users with **control over their data** and **transparency about data usage**.

#### **Key Considerations:**
- Are users able to **opt out of data collection** or **data sharing**?
- Is there a **clear privacy notice** explaining how data is used, stored, and shared?
- Are users informed about the **potential risks** of data exposure (e.g., employer or insurer access)?

---

### **HERA Dimension: Ethical Use & Harm Prevention**  
**[P7.D1]**  
Even though the app is **Class I**, the **relapse-risk score** could have **psychological

### USER
None outside the app; clinic integration only on opt-in with explicit consent.

### ASSISTANT
Excellent! Based on your clarification that **no data is shared outside the app** except for **clinic integration**, which is **opt-in with explicit consent**, we can now focus on **specific regulatory and ethical risks** under the **HERA taxonomy** and **relevant regulations** (GDPR, MDR, EU AI Act, ISO 82304-2).

---

### 🔍 **HERA Dimension: Data Protection & Privacy [P3.D1]**

#### ✅ **Strengths:**
- **No third-party sharing** outside the app, except for **clinic integration** (which is **opt-in with explicit consent**), aligns well with **GDPR Article 6** (legal basis for processing) and **Article 9** (special categories of data) [card_gdpr_base · p.0].
- **Explicit consent** for clinic integration is a **key compliance measure** under **GDPR Article 9(2)(a)** and **ePrivacy Regulation Article 5(3)** [card_data_monetization · p.0].

#### 🚨 **Risks:**
- **Data minimization** is still critical: Are you only collecting the **minimum necessary data** (e.g., substance logs, relapse-risk scores) to provide the service?
- **Security measures**: Are you implementing **appropriate technical and organizational measures** (e.g., encryption, access controls) to protect user data? [GDPR Article 30, Article 32]

---

### 🔍 **HERA Dimension: Data Monetization & Third-Party Sharing [P5.D1]**

#### ✅ **Strengths:**
- **No monetization** or **third-party sharing** outside the app, except for **clinic integration** (which is **opt-in with explicit consent**), reduces the risk of **data monetization** and **ePrivacy violations** [card_data_monetization · p.0].

#### 🚨 **Risks:**
- **Clinic integration** could involve **health data sharing**, which must be **explicitly consented** and **documented** under **GDPR Article 9(2)(a)** and **ePrivacy Regulation Article 5(3)**.
- If the clinic integration involves **data transfer to non-EU countries**, you must ensure **adequate safeguards** (e.g., **standard contractual clauses**, **binding corporate rules**) under **GDPR Article 44–49** [card_gdpr_transfer · p.0].

---

### 🔍 **HERA Dimension: User Control & Transparency [P6.D1]**

#### ✅ **Strengths:**
- **Explicit consent** for clinic integration is a **key compliance measure** under **GDPR Article 9(2)(a)** and **ePrivacy Regulation Article 5(3)** [card_data_monetization · p.0].
- **Privacy notice** and **transparency** about data usage is likely in place, which is a **key requirement** under **GDPR Article 13–14** [card_gdpr_base · p.0].

#### 🚨 **Risks:**
- **User control** over data: Are users able to **opt out of data collection** or **data sharing** (e.g., with clinics)?
- **Data minimization**: Are you only collecting the **minimum necessary data** to provide the service?
- **Transparency**: Is the **privacy notice** clear and **child-friendly** (if minors are users)? [card_gdpr_children · p.0]

---

### 🔍 **HERA Dimension: Ethical Use & Harm Prevention [P7.D1]**

#### ✅ **Strengths:**
- **Strict privacy posture** reduces the risk of **data exposure** to employers or insurers, which aligns with **GDPR Article 9** and **ePrivacy Regulation Article 5(3)**.
- **Relapse-risk score** is **informational**, not diagnostic, which reduces the risk of **misleading users** or **overly deterministic behavior**.

#### 🚨 **Risks:**
- **Psychological impact**: Could the **relapse-risk score** cause **unnecessary anxiety** or **self-diagnosis**? This is an **ethical concern** under **P7.D1**.
- **Model transparency**: If the **relapse-risk score** is based on **machine learning**, is the **model transparent** and **explainable** to users? This is a **key requirement** under the **EU AI Act** (Article 13, 52–54) [card_ai_act · p.0].

---

### 🔍 **HERA Dimension: Accessibility & Inclusive Design [P4.D1]**

#### ✅ **Strengths:**
- **Peer-support chat** and **onboarding flows** suggest a focus on **user experience**, which is a **key requirement** under

### USER
None outside the app; clinic integration only on opt-in with explicit consent.

### ASSISTANT
Great! Based on your clarification that **no data is shared outside the app** except for **clinic integration**, which is **opt-in with explicit consent**, we can now focus on **specific regulatory and ethical risks** under the **HERA taxonomy** and **relevant regulations** (GDPR, MDR, EU AI Act, ISO 82304-2).

---

### 🔍 **HERA Dimension: Data Protection & Privacy [P3.D1]**

#### ✅ **Strengths:**
- **No third-party sharing** outside the app, except for **clinic integration** (which is **opt-in with explicit consent**), aligns well with **GDPR Article 6** (legal basis for processing) and **Article 9** (special categories of data) [card_gdpr_base · p.0].
- **Explicit consent** for clinic integration is a **key compliance measure** under **GDPR Article 9(2)(a)** and **ePrivacy Regulation Article 5(3)** [card_data_monetization · p.0].

#### 🚨 **Risks:**
- **Data minimization** is still critical: Are you only collecting the **minimum necessary data** (e.g., substance logs, relapse-risk scores) to provide the service?
- **Security measures**: Are you implementing **appropriate technical and organizational measures** (e.g., encryption, access controls) to protect user data? [GDPR Article 30, Article 32]

---

### 🔍 **HERA Dimension: Data Monetization & Third-Party Sharing [P5.D1]**

#### ✅ **Strengths:**
- **No monetization** or **third-party sharing** outside the app, except for **clinic integration** (which is **opt-in with explicit consent**), reduces the risk of **data monetization** and **ePrivacy violations** [card_data_monetization · p.0].

#### 🚨 **Risks:**
- **Clinic integration** could involve **health data sharing**, which must be **explicitly consented** and **documented** under **GDPR Article 9(2)(a)** and **ePrivacy Regulation Article 5(3)**.
- If the clinic integration involves **data transfer to non-EU countries**, you must ensure **adequate safeguards** (e.g., **standard contractual clauses**, **binding corporate rules**) under **GDPR Article 44–49** [card_gdpr_transfer · p.0].

---

### 🔍 **HERA Dimension: User Control & Transparency [P6.D1]**

#### ✅ **Strengths:**
- **Explicit consent** for clinic integration is a **key compliance measure** under **GDPR Article 9(2)(a)** and **ePrivacy Regulation Article 5(3)** [card_data_monetization · p.0].
- **Privacy notice** and **transparency** about data usage is likely in place, which is a **key requirement** under **GDPR Article 13–14** [card_gdpr_base · p.0].

#### 🚨 **Risks:**
- **User control** over data: Are users able to **opt out of data collection** or **data sharing** (e.g., with clinics)?
- **Data minimization**: Are you only collecting the **minimum necessary data** to provide the service?
- **Transparency**: Is the **privacy notice** clear and **child-friendly** (if minors are users)? [card_gdpr_children · p.0]

---

### 🔍 **HERA Dimension: Ethical Use & Harm Prevention [P7.D1]**

#### ✅ **Strengths:**
- **Strict privacy posture** reduces the risk of **data exposure** to employers or insurers, which aligns with **GDPR Article 9** and **ePrivacy Regulation Article 5(3)**.
- **Relapse-risk score** is **informational**, not diagnostic, which reduces the risk of **misleading users** or **overly deterministic behavior**.

#### 🚨 **Risks:**
- **Psychological impact**: Could the **relapse-risk score** cause **unnecessary anxiety** or **self-diagnosis**? This is an **ethical concern** under **P7.D1**.
- **Model transparency**: If the **relapse-risk score** is based on **machine learning**, is the **model transparent** and **explainable** to users? This is a **key requirement** under the **EU AI Act** (Article 13, 52–54) [card_ai_act · p.0].

---

### 🔍 **HERA Dimension: Accessibility & Inclusive Design [P4.D1]**

#### ✅ **Strengths:**
- **Peer-support chat** and **onboarding flows** suggest a focus on **user experience**, which is a **key requirement** under

### USER
None outside the app; clinic integration only on opt-in with explicit consent.

### ASSISTANT
Great! Based on your clarification that **no data is shared outside the app** except for **clinic integration**, which is **opt-in with explicit consent**, we can now focus on **specific regulatory and ethical risks** under the **HERA taxonomy** and **relevant regulations** (GDPR, MDR, EU AI Act, ISO 82304-2).

---

### 🔍 **HERA Dimension: Accessibility & Inclusive Design [P4.D1]**

#### ✅ **Strengths:**
- **Peer-support chat** and **onboarding flows** suggest a focus on **user experience**, which is a **key requirement** under **ISO 82304-2** (for mHealth apps) [card_iso_82304 · p.0].
- **Opt-in consent** for clinic integration aligns with **GDPR Article 6(1)(a)** and **Article 9(2)(a)**, ensuring **user autonomy** and **inclusive design**.

#### 🚨 **Risks:**
- **Language accessibility**: Is the **privacy notice** and **consent mechanism** available in **multiple languages** to accommodate non-native speakers or users with limited literacy?
- **User interface**: Is the **consent process** and **data-sharing mechanism** **simple, clear, and accessible** for users with **cognitive or physical disabilities**? [ISO 82304-2, P4.D1]
- **Child-friendly design**: If the app is used by **minors**, is the **interface** and **consent process** **age-appropriate** and **aligned with GDPR Article 8** and **Article 9(2)(a)** [card_gdpr_children · p.0]?

---

### 🔍 **HERA Dimension: Security & Data Integrity [P2.D2]**

#### ✅ **Strengths:**
- **No third-party sharing** reduces the attack surface and aligns with **GDPR Article 30** (data protection impact assessments) and **Article 32** (security of processing).
- **Clinic integration** is **opt-in with explicit consent**, which is a **key requirement** under **GDPR Article 9(2)(a)** and **ePrivacy Regulation Article 5(3)**.

#### 🚨 **Risks:**
- **Data encryption**: Are you implementing **end-to-end encryption** for **health data** (e.g., substance logs, relapse-risk scores) to ensure **data integrity** and **confidentiality**? [GDPR Article 30, Article 32]
- **Secure API integration**: If the app integrates with **clinical systems**, are you using **secure APIs** and **authentication mechanisms** (e.g., OAuth 2.0) to protect **data integrity** and **prevent unauthorized access**? [ISO 82304-2, P2.D2]
- **Data breach response**: Do you have a **clear data breach response plan** in place, including **notification procedures** and **user support**? [GDPR Article 33, Article 34]

---

### 🔍 **HERA Dimension: Ethical Use & Harm Prevention [P7.D1]**

#### ✅ **Strengths:**
- **Strict privacy posture** reduces the risk of **data exposure** to employers or insurers, which aligns with **GDPR Article 9** and **ePrivacy Regulation Article 5(3)**.
- **Relapse-risk score** is **informational**, not diagnostic, which reduces the risk of **misleading users** or **overly deterministic behavior**.

#### 🚨 **Risks:**
- **Psychological impact**: Could the **relapse-risk score** cause **unnecessary anxiety** or **self-diagnosis**? This is an **ethical concern** under **P7.D1**.
- **Model transparency**: If the **relapse-risk score** is based on **machine learning**, is the **model transparent** and **explainable** to users? This is a **key requirement** under the **EU AI Act** (Article 13, 52–54) [card_ai_act · p.0].

---

### 🔍 **HERA Dimension: Legal Compliance & Regulatory Alignment [P1.D1]**

#### ✅ **Strengths:**
- **No third-party sharing** and **opt-in clinic integration** align with **GDPR Article 6(1)(a)**, **Article 9(2)(a)**, and **ePrivacy Regulation Article 5(3)**.
- **Explicit consent** for clinic integration is a **key requirement** under **GDPR Article 9(2)(a)** and **Article 13–14**.

#### 🚨 **Risks:**
- **Cross-border data transfers**: If the **clinic integration** involves **

### USER
DE, FR, IT, EN; low-literacy mode.

### ASSISTANT
Excellent! You've specified that the app supports **multiple languages** (DE, FR, IT, EN) and is designed for **low-literacy users**. This is a **key consideration** for **user accessibility**, **legal compliance**, and **ethical design** under the **HERA taxonomy**.

---

### 🔍 **HERA Dimension: Accessibility & Inclusive Design [P4.D1]**

#### ✅ **Strengths:**
- **Multilingual support** (DE, FR, IT, EN) aligns with **GDPR Article 22** (non-discrimination) and **ISO 82304-2** (for mHealth apps) [card_iso_82304 · p.0].
- **Low-literacy mode** supports **user autonomy** and **inclusive design**, which is a **key requirement** under **ISO 82304-2** and **GDPR Article 12–14** [card_gdpr_base · p.0].

#### 🚨 **Risks:**
- **Language clarity**: Are the **privacy notices**, **consent mechanisms**, and **data-sharing explanations** written in **simple, clear language** for low-literacy users? [ISO 82304-2, P4.D1]
- **Visual design**: Is the **interface** and **consent process** **visually accessible**, with **icons**, **high contrast**, and **large fonts** for users with **limited literacy or visual impairments**? [ISO 82304-2, P4.D1]
- **Child-friendly design**: If the app is used by **minors**, is the **interface** and **consent process** **age-appropriate** and **aligned with GDPR Article 8** and **Article 9(2)(a)** [card_gdpr_children · p.0]?

---

### 🔍 **HERA Dimension: User Control & Transparency [P6.D1]**

#### ✅ **Strengths:**
- **Opt-in consent** for clinic integration is a **key compliance measure** under **GDPR Article 9(2)(a)** and **ePrivacy Regulation Article 5(3)** [card_data_monetization · p.0].
- **Multilingual support** ensures **transparency** across **different user groups**, which is a **key requirement** under **GDPR Article 13–14** [card_gdpr_base · p.0].

#### 🚨 **Risks:**
- **Consent clarity**: Is the **consent process** and **data-sharing mechanism** **simple, clear, and accessible** for users with **low-literacy** or **limited language proficiency**? [ISO 82304-2, P4.D1]
- **User control**: Are users able to **opt out of data collection** or **data sharing** (e.g., with clinics) at any time? [GDPR Article 7, Article 16]

---

### 🔍 **HERA Dimension: Legal Compliance & Regulatory Alignment [P1.D1]**

#### ✅ **Strengths:**
- **Multilingual support** and **low-literacy mode** align with **GDPR Article 22** (non-discrimination) and **Article 12–14** (transparency) [card_gdpr_base · p.0].
- **Opt-in clinic integration** is a **key requirement** under **GDPR Article 9(2)(a)** and **ePrivacy Regulation Article 5(3)**.

#### 🚨 **Risks:**
- **Cross-border data transfers**: If the **clinic integration** involves **data transfers to countries outside the EU**, are you **adequately protecting user data** under **GDPR Article 44–49** (e.g., via SCCs or adequacy decisions)? [card_gdpr_data_transfers · p.0]
- **Data minimization**: Are you only collecting the **minimum necessary data** for the **relapse-risk score** and **peer-support chat**? [GDPR Article 5(1)(c)]

---

### 🔍 **HERA Dimension: Ethical Use & Harm Prevention [P7.D1]**

#### ✅ **Strengths:**
- **Strict privacy posture** reduces the risk of **data exposure** to employers or insurers, which aligns with **GDPR Article 9** and **ePrivacy Regulation Article 5(3)**.
- **Relapse-risk score** is **informational**, not diagnostic, which reduces the risk of **misleading users** or **overly deterministic behavior**.

#### 🚨 **Risks:**
- **Psychological impact**: Could the **relapse-risk score** cause **unnecessary anxiety** or **self-diagnosis**? This is an **ethical concern** under

### USER
DE, FR, IT, EN; low-literacy mode.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
### 📋 **HERA Risk & Safety Report (Structured by Severity)**

---

#### **High Severity Risks**  
These risks require **immediate mitigation** to ensure **legal compliance**, **user safety**, and **ethical integrity**.

| **HERA Dimension** | **Risk Description** | **Mitigation** | **Regulation / Standard** |
|--------------------|----------------------|----------------|-----------------------------|
| **[P1.D1]** | **Lack of explicit consent for clinic integration** | Ensure all data sharing with clinics is **opt-in with clear, multilingual explanations**. | GDPR Article 6(1)(a), 9(2)(a), ePrivacy Regulation Article 5(3) |
| **[P2.D2]** | **Data encryption and security gaps** | Implement **end-to-end encryption** for all health data, including relapse-risk scores and substance logs. | GDPR Article 32, ISO 82304-2 |
| **[P4.D1]** | **Language and literacy barriers in consent and privacy notices** | Use **simple, clear language** and **visual aids** for low-literacy users. | GDPR Article 12–14, ISO 82304-2 |
| **[P6.D1]** | **User control over data sharing** | Allow users to **opt out of data sharing** at any time with clear instructions. | GDPR Article 7, 16 |
| **[P7.D1]** | **Psychological harm from relapse-risk score** | Ensure the **relapse-risk score is framed as informational**, not diagnostic, and avoid **overly deterministic messaging**. | EU AI Act Article 52–54, ISO 82304-2 |

---

#### **Medium Severity Risks**  
These risks require **planned mitigation** to avoid **regulatory non-compliance** or **ethical concerns**.

| **HERA Dimension** | **Risk Description** | **Mitigation** | **Regulation / Standard** |
|--------------------|----------------------|----------------|-----------------------------|
| **[P1.D2]** | **Cross-border data transfers without adequacy decisions** | Use **Standard Contractual Clauses (SCCs)** or **adequacy decisions** for data transfers to non-EU countries. | GDPR Article 44–49 |
| **[P4.D1]** | **Visual accessibility for low-literacy users** | Use **high-contrast visuals**, **icons**, and **large fonts** for interface elements. | ISO 82304-2 |
| **[P6.D2]** | **Lack of transparency in data usage** | Provide **clear, multilingual explanations** of how data is used (e.g., for relapse-risk scores). | GDPR Article 13–14 |
| **[P7.D2]** | **Potential for algorithmic bias in relapse-risk score** | Conduct **bias audits** and ensure **transparency in model development**. | EU AI Act Article 52–54 |

---

#### **Low Severity Risks**  
These risks are **manageable** with **standard practices** and may not require **immediate action**.

| **HERA Dimension** | **Risk Description** | **Mitigation** | **Regulation / Standard** |
|--------------------|----------------------|----------------|-----------------------------|
| **[P1.D3]** | **Limited multilingual support for non-core features** | Ensure **core features** (e.g., consent, privacy notices) are available in all supported languages. | GDPR Article 22, ISO 82304-2 |
| **[P3.D1]** | **Lack of data minimization for non-core features** | Limit data collection to **only what is necessary** for core functionality. | GDPR Article 5(1)(c) |
| **[P5.D1]** | **Limited user control over peer-support chat content** | Allow users to **opt out of peer-support chat** or **report inappropriate content**. | GDPR Article 16 |

---

### 📌 **Dimensions Not Covered in This Report**

The following **HERA dimensions** were not explicitly addressed in this risk report and may require further evaluation:

- **[P3.D2]** – Data retention and deletion policies
- **[P5.D2]** – User reporting and content moderation
- **[P8.D1]** – Environmental and sustainability impact
- **[P9.D1]** – Accessibility for users with disabilities beyond low-literacy

---

### 📌 **Next Steps**

- Conduct a **comprehensive DPIA (Data Protection Impact Assessment)** for the relapse-risk score.
- Perform **bias audits** and **transparency assessments** for the AI model.
- Ensure **multilingual support** is implemented for all **core user-facing features

Now produce the JSON judgement object.